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Abstract: The pathophysiology of depression is related to neurobiological changes that occur in 
the monoamine system, hypothalamic-pituitary-adrenal axis, neurogenesis system and the 
neuroimmune system. In recent years, there has been a growing interest in the research of the 
effects of exercise on brain function, with a special focus on its effects on brainderived 
neurotrophic factor (BDNF), cortisol and other biomarkers. Thus, the aim of this study is to 
present a review investigating the acute and chronic effects of aerobic exercise on BDNF and 
cortisol levels in individuals with depression. It was not possible to establish an interaction 
between aerobic exercise and concentration of BDNF and cortisol, which may actually be the 
result of the divergence of methods, such as type of exercises, duration of the sessions, and 
prescribed intensity and frequency of sessions. 




Depression is related to several neurobiological changes [1, 2]. Research on the possible 
molecular pathways of depression demonstrated that the increased cell dysfunction in cortical 
and limbic areas of the brain can be observed in individuals suffering from depression [3, 4] and 
is strongly related to the decrease in neurotrophic activity [5]. Therefore, the investigation of 
biomarkers, such as brainderived neurotrophic factor (BDNF), has attracted great interest, in 
order to clarify its role in the pathophysiology of depression [6]. BDNF is a protein expressed 
mainly in the central nervous system (CNS), and it has an important role in the survival and 
maintenance of neuronal function [7]. In fact, a low neurotrophic activity is associated with 
reduced numbers of cells in the prefrontal cortex [8], amygdala [9, 10] and a decrease in 
hippocampal volume [11, 12], indicating that the growth nerve factors, and more specifically, 
the changes in BDNF may play an important role in the development of depression [3, 4, 13-15]. 
Furthermore, the dysfunction of the hypothalamuspituitary-adrenal (HPA) axis has been the 
most valid neurobiological theory to explain the pathophysiology of depression. The HPA axis is 
the interaction between the hypothalamus, pituitary gland, and the adrenal cortex, and is a 
major part of the neuroendocrine system that controls reactions to stress [16]. The clinical 
manifestation of its dysfunction in depression includes basal hypercortisolemia [17], elevated 
cortisol secretion in the dexamethasone suppression test [18], and increased cortisol release in 
the combined dexamethasone suppression-corticotropine releasing hormone stimulation test 
[19, 20]. The first line of treatment for depression is the use of antidepressants [21]. However, 
the remission rate with selective serotonin reuptake inhibitor (SSRI), which is currently the first-
line treatment for depression, is only 60% [22]. Exercise is a readily available therapeutic option, 
effective as a treatment in mild to moderate depression [23] Regular exercise may bring 
physiological, psychological and social benefits to its practitioners [24-26]. Given that sedentary 
is a recognized risk factor [23] for many diseases, exercise has become a topic of great interest 
to many researchers. Thus, the practice of exercises has been increasingly recommended in 
health promotion programs by institutions such as the Center for Disease Control and 
Prevention (CDP) and the American College of Sports Medicine (ACSM) as a non-
pharmacological means of prevention and treatment of psychiatric disorders such as depression 
[27, 28]. The effectiveness of exercise on depression has been attributed to its impact on the 
modification of certain neurobiological mechanisms such as: influence on monoamine 
metabolism by increasing serotonin levels; regulating function of the HPA axis, with possible 
reduction in cortisol secretion; increase in neurotrophic factors such as BDNF and hippocampal 
neurogenesis and, finally, reducing neuroinflammation through a decrease in proinflammatory 
mediators [29-38]. Ida et al. [21] examined the acute effects of aerobic exercise performed in 
cycloergometer in the salivary cortisol levels as well as the scores of subjective symptoms of 
depression in patients diagnosed by Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV). The salivary cortisol levels were measured pre-exercise and postexercise. The same 
patients returned after a month for a control session (sitting quietly), where the salivary cortisol 
levels were measured pre- and post-session. The authors concluded that a session of 15 minutes 
of moderate intensity aerobic exercise could reduce salivary cortisol levels. In addition, a 
decrease in salivary cortisol level was statistically correlated with a decrease in the scores of 
subjective symptoms of depression. It is noteworthy that all patients were being treated with 
antidepressant medications during the study, and in addition, subjective depression scores used 
in this study have not yet been validated on a large scale. A new view on the benefits of regular 
practice of physical exercise has been discussed in some studies that show the anti-inflammatory 
effects of exercise [21, 39]. There is evidence that shows that exercise performed at a moderate 
intensity may be an important factor in prevention and treatment, not only of metabolic 
diseases [26, 40, 41], but also of symptomatology and cognitive function in mood disorders [42, 
43], although its physiological effects still remain uncertain. Thus, in recent years there has been 
increasing interest in research on the effects of exercise on brain function, with a special focus 
on its effects on BDNF, cortisol and other biomarkers [44]. This study aimed to review the acute 
and chronic of aerobic exercise on BDNF and cortisol levels in depressed patients. Here, we will 
review the basic foundation of BDNF and cortisol, their role in healthy and depressed people 
and the experimental advances of aerobic exercise on BDNF and cortisol in depressed patients 
that can become viable as clinical applications in the coming years for major depression (MD). A 
literature search was conducted using the databases PubMed, ISI Web of Knowledge and 
PsycInfo using the following terms and their combinations: “aerobic exercise”, “depression”, 
“brain derived neurotrophic factor”, “cortisol”, and "biomarkers". All articles were published 
between 1995 and 2015 and in English. Additional references were identified through hand 
search of the possessed articles. 
 
BDNF: ISOFORMS AND RECEPTORS The neurotrophic growth factors, known as neurotrophins, 
are proteins whose main function is the development of neurons, contributing for their survival, 
growth and characterization [45, 46]. The family of neurotrophins includes the nerve growth 
factor (NGF), the neurotrophic growth factor derived from the BDNF, the neurotrophin-3 (NT-3) 
and the neurotrophin-4/5 (NT-4/5) [45, 47]. Their biologically active forms show about 50% 
amino acid identity. The genes encoding neurotrophins are expressed not only during 
development but also in the adulthood, in a variety of tissues, including the CNS [48]. 
Neurotrophins sustain the neuroplasticity (i.e., ability of the CNS to adapt to environmental 
changes, respond to injury and acquire new information, modifying neural connectivity and 
function) and are capable of signaling neurons to survive, differentiate, or grow [49, 50]. 
Neurotrophins interact with two distinct classes of receptors [47]. The first to be discovered was 
the neurotrophin receptor 75 p-(p-75NTR) [51, 52], which belongs to the family of receptors of 
the tumor necrosis factor (TNF) [47]. The second class of neurotrophin receptors includes the 
receptors for tropomyosin-related kinase (TrK, tyrosine kinase). All neurotrophins bind to the 
receptor p-75NTR, but neurotrophins bind with greater affinity to its specific receptor TrK [52]. 
In particular, NGF binds to TrkA, BDNF and NT-4/5 bind to  and NT3 binds with greater affinity 
to TrkC [53]. Among these neurotrophins, BDNF has attracted great interest as a functional 
candidate gene in several mental disorders. The BDNF gene is located on chromosome 11p13 
reverse strand and encodes a precursor peptide pro-BDNF [54]. In fact, all neurotrophins, 
including BDNF, are synthesized as a pre-pro neurotrophic precursor. In particular, pro-BDNF 
preferably activates p75NTR to mediate the programmed neuronal death [55], to reduce the 
complexity and density of the dendrites of hippocampal neurons [56] and to induce long-term 
depression of synaptic transmission [57, 58]. The function of a receptor for BDNF (i.e., TrkB) is 
also regulated in an activity-dependent manner, as TrkB is mainly located in synapses. In 
addition, BDNF can be found in synapses after neuronal activity [59]. The neuronal activity, 
however, is essential for the synthesis and intracellular targeting of TrkB receptors. Thus, the 
release of BDNF and TrkB receptors expression in a coordinated manner are important for 
optimal synaptic response [60]. 
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THE ROLE OF BDNF AND CORTISOL IN HEALTHY HUMANS 
BDNF, which is an essential neurotrophin connected directly to the central and peripheral 
molecular processes of energy metabolism and homeostasis, may play a key role in these 
induced mechanisms [61]. BDNF has a repertoire of neurotrophic and neuroprotective 
properties in the CNS and the periphery [62- 64]. The effect of BDNF on the plasticity of the CNS 
involves elements of cellular energy metabolism and in the periphery participates in metabolic 
processes. Prime examples come from studies of transgenic mice heterozygous for BDNF, which 
suffer from hyperphagia, obesity and hyperinsulinemia [65, 66]. Tonra [67] demonstrated that 
central or peripheral administration of BDNF reduces body weight and improves glycemic 
control in obese diabetics. BDNF also appears to be a positive regulator of energy expenditure, 
and BDNF has shown to be effective in preventing reduction in body temperature during cold 
exposure or food deprivation [68]. Furthermore, Wu et al. [69] reported that increase in 
oxidative stress, which would be a consequence of aberrant energy metabolism, result in 
decreased BDNF levels. BDNF works toward neuronal protection and survival, axonal and 
dendritic growth and remodeling, neuronal differentiation and synaptic activity 
(synaptogenesis) and has efficacy in synaptic transmission [70, 71]. In the periphery, BDNF 
function is to increase lipid oxidation in skeletal muscle through the activation of activated 
kinase protein (AMPK) [72]. A human case study showed a clinical phenotype of impaired 
cognitive function, hyperactivity and severe obesity associated with a chromosomal inversion of 
a region encompassing the BDNF gene, and a reduction in serum BDNF [73]. Furthermore, Araya 
et al. [74] demonstrated that plasma BDNF was increased in insulin resistant individuals, 
overweight subjects and obese subjects following a reducedcalorie diet. These findings reinforce 
the fact that BDNF is essential not only in the neuronal system, but are also strongly linked to 
the central and peripheral molecular processes of energy metabolism and homeostasis [75, 76]. 
With regard to cortisol, which is released by the cortex of the adrenal gland, it is the main 
glucocorticoid to be directly involved in the regulation of plasma glucose [77]. Glucocorticoids 
are widely distributed in the brain, specifically concentrated in the hippocampus, amygdala and 
hypothalamus [78]. Cortisol is not only part of the circadian system, but helps to organize it. 
Corticosteroids act on the glucocorticoid and mineralocorticoid receptors [79]. Steroids also act 
over receptors linked to genomic membrane, which may play a role on neuronal function [80]. 
HPA axis responds quickly to a range of environmental and internal factors, which are often 
associated to stress [16]. Although cortisol performs a feedback function at the level of the 
pituitary gland, hypothalamus and hippocampus, prolonged stress can stimulate secretion over 
several hours. After stimulation by adrenocorticotropin (ACTH), cortisol is synthesized and 
secreted by the adrenal gland and released into the blood, circulating quickly on carriers such as 
corticosteroid-binding globulin, albumin and erythrocytes. Only a small fraction of cortisol (2-
15%) remains free. It is just that fraction of free hormone that causes the multitude of cortisol 
related genomic effects in peripheral tissues and the brain [81]. It is also known that about 30 
to 60 minutes after awakening, there is an increase in cortisol secretion [82], but the area or the 
type of receptor that may be involved in the risk posed by this change has not yet been 
established [83]. 
 
THE ROLE OF BDNF AND CORTISOL IN DEPRESSION 
The pathophysiology of depression has been associated with dysregulation of the HPA axis [84]. 
Hyperactivity of the HPA is one of the most robust and consistent neurobiological findings in 
patients with MD, and cortisol have been suggested as a potential biomarker of this disease [85, 
86]. The cortisol contributes to genetic variants increasing the risk of developing MD, so that 
environmental events may extend such a risk. The influence of corticosteroids begins prenatally, 
but continues during adulthood. The impact of cortisol in each phase depends not only on their 
interaction with other factors, such as psychological traits and genetic variants, but also on the 
events that have or not previously occurred [87]. There is little doubt that cortisol plays a central 
role in the onset and course of depression, but there is still considerable uncertainty about what 
exactly that role is [87]. The daily cortisol rhythms are disturbed in about half the cases of MD 
[88]. There is an increase of resistance to the action of glucocorticoid feedback on the HPA 
activity in a proportion of cases of DM [89, 90]. The post-awakening cortisol increase and 
prolonged excessive levels can result in DM [91-96]. Cortisol levels in excess can put the brain at 
risk, making it more vulnerable to harmful agents that in the absence of corticoids would not 
necessarily be harmful [97, 98]. This notion can be translated to the MD, since that adversity 
predisposes to this disorder [99, 100], and increased cortisol can potentiate the 
psychopathological actions of these agents in a similar way [101]. The development and 
maintenance of the vertebrate nervous system requires continuous operation of a number of 
proteins called neurotrophins. It has been shown that in the adult brain occurs the proliferation 
and maturation of neurons in discrete areas including the hippocampus and the striatal 
subventricular area. Exposure to psychotropic substances or stressors mediates the process of 
adult neurogenesis by regulating the expression and function of some growth factors, suggesting 
a possible role of neurogenesis in the pathophysiology of MD [102, 103]. The physiological role 
of BDNF is to stimulate the development and stabilization of connections between neurons. This 
growth factor influences the expression levels of reelin, a molecule of the extracellular matrix 
that plays an important role in the processes of neural plasticity in important areas for plasticity 
and memory, such as the hippocampus and cortex, as well as other components of the limbic 
system and amygdala [104]. Furthermore, both BDNF as well as glutamate are involved in the 
process of synaptic plasticity, neurogenesis and neural survival in the adult brain. In fact, both 
signals are co-regulated: glutamate stimulates the expression of BDNF, so that there is an 
increase in the growth and survival of glutamatergic neurons [105]. There is much evidence of a 
possible validity of BDNF as a biomarker of MD, as follows: low levels of this marker in the blood 
of depressed individuals; a negative correlation between blood levels of BDNF and Hamilton 
scale score of patients with depression; as well as increases in hippocampal BDNF expression in 
subjects treated with antidepressants compared to healthy controls [106, 107]. The basic 
assumption is that MD is caused by a maladaptation to the plasticity of the brain, and 
antidepressants act allowing renewed plasticity that somehow restores normal function [108]. 
Exactly where and how this occurs and how could explain the MD was not specified, although 
the hippocampus is an obvious target in this process, which contains high concentrations of both 
BDNF and its main receptor, TkrB. 
 
THE EFFECT OF AEROBIC EXERCISE ON THE PLASMA OR SERUM CORTISOL CONCENTRATIONS IN 
DEPRESSIVE PATIENTS 
Few studies have analyzed the relationship between serum cortisol levels and aerobic exercise 
in patients with depression [21, 32, 109-112]. Krogh et al. [109] investigated whether an exercise 
intervention for four months could change the hormonal response to acute exercise in 
depressed patients. The study consisted of two phases. In the first phase (i.e., acute), were 
recruited 44 healthy individuals (GC), without physical and mental disorders, who did not 
practice any physical activity for more than an hour a week, and had anthropometric 
characteristics corresponding to those of depressed patients (n = 137). The responses of serum 
growth hormone (GH), prolactin and cortisol in depressed patients were compared with GC, 
adopting an incremental test on a cycloergometer as exercise for patients. After that (i.e., 2nd 
phase), the responses of these hormones after 4 months of intervention using three different 
exercise modalities in depressed individuals were investigated. Randomization was centralized 
and stratified according to antidepressant medication: 1) have not received any antidepressant 
medication; 2) have received an antidepressant medication for less than six weeks and 3) have 
received an antidepressant medication for more than six weeks. The sample consisted of 137 
adults with MD (38.9 ± 9.6 years) and 44 adult control subjects (38.2 ± 10.2 years). For the 
chronic study (second stage), the sample was divided as follows: relaxation (n = 28); aerobic (n 
= 31); and strength training (n = 29). All groups underwent their activities twice a week. All 
groups were divided into age: relaxation (36 ± 9.8 years); aerobic (39.3 ± 9.8 years) and strength 
training (42.4 ± 9.5 years). However, the control group consisted of healthy subjects who did not 
use antidepressants. Aerobic training group consisted of a circuit of cyclical activities, which 
involved large muscle groups. Strength training group consisted of ten exercises using machines 
and free weights. Relaxation exercises group consisted of stretching exercises prescribed as a 
way of socializing, at a low intensity. Results showed that there were differences in cortisol 
response to the incremental test among groups, where the group of healthy subjects showed 
higher concentrations in serum. However, at the end of the four month intervention, no 
difference was found in baseline values of the hormones investigated among the three groups, 
as well as there were no significant changes in cortisol levels after the incremental test on 
cycloergometer. It is well described that in times of stress, there is increased secretion of 
cortisol. Therefore, the difference found in the incremental test may have happened because 
the depressed group makes use of antidepressant medication, which may have influenced an 
increasing nonproportional to the effort. Although authors found no evidence for greater 
variation due to use of antidepressants, this could be considered as a limitation of the study, 
since these medication have chronic effects on the HPA axis and monoamines. Nabkasorn et al. 
[32] investigated the effect of exercise on depressive state, in the concentration of cortisol in 
urine and physiological variables of fitness. The study was carried out on samples without a 
clinical diagnosis of depression, but with some symptoms, while the studies of Krogh [109], 
Garcia [110], Wied [111] and Kiive [112] were conducted on clinical samples. The study included 
49 female adolescents (18.8 ± 0.7 years) with mild to moderate depressive symptoms. The 
exercise protocols consisted of recreational activities and training. The sample was divided into 
two groups. The group A began with the eight-week training, and group B participated only usual 
activities, serving as a control. After eight weeks, there was a reassessment. After this 
procedure, there was alternation of activity between the groups, with group A began performing 
recreational activities and group B began performing training. In the training protocol, the 
exercise performed was running at a lower intensity than 50% of maximum heart rate reserve. 
The group that began the study with recreational activities and then was moved to training 
showed a higher decrease in the concentration of cortisol in urine than the other group. 
However, data showed a significant decrease in the concentration of cortisol in the urine in both 
groups after 16 weeks compared to pre-intervention period. Perhaps because the group B was 
the last receiving training, may have showed a greater training effect on the studied variables. 
The limitation of this study was not having used a structured psychiatric interview to assess the 
individuals, which were classified with mild to moderate depressive symptoms by Center for 
Epidemiologic Studies Depression Scale (CESD). This instrument is a self-report scale, widely 
used as a screening tool, especially used in primary care and outpatient, but represent the 
symptoms over the previous week and may include more transient or temporary symptoms than 
other measures. In addition, five individuals of the group who started with training participated 
of an exercise class again in the period in which no exercise was scheduled. Thus, these 
individuals were excluded of the data analysis in order to do not influence the results of this 
group after training. At last, the sample consisted of female adolescents without clinical 
depression and these results cannot be generalized to other populations with different ages and 
different levels of depressive symptoms. Thus, it is important to highlight the role of chronic 
exercise on this marker in depressed patients. It appears that regular exercise can influence long-
term treatment of MD. Garcia et al. [110] evaluated serum cortisol levels response to the 
incremental cycloergometer test. The study included 43 adults, 23 of which belonged to the 
depressed (mild and moderate) groups (43.5 ± 1.8 years). Fourteen participants had mild 
depression and 9 moderate depression. The 20 individuals in the control group (42.8 ± 3.0 years) 
were healthy. At baseline, serum cortisol levels were significantly lower in both groups of 
depressed, compared to the control group. Immediately after exercise, and also thirty minutes 
later, both the control group and the mild depression group had higher levels of cortisol, while 
the group with moderate depression remained with lower cortisol levels. At 90 minutes after 
exercise, the control group and the patients with moderate depression showed a reduction in 
cortisol levels in relation to levels of cortisol peak, which was amended in individuals with 
moderate depression. It seems that just an exercise session is not enough to influence positive 
adaptations in cortisol levels, considering that this session also led individuals to exhaustion, 
resulting in greater metabolic stress. It is known that the use of antidepressants can influence 
on different responses of cortisol in patients with depression, and an important limitation in the 
study was because the authors did not describe whether depressed patients used 
antidepressant medication. Therefore, we need to know whether this finding applies to severe 
depressed who do not use antidepressant medication. In another experiment, Wied et al. [111] 
sought to determine whether depressive symptoms affect the pituitaryadrenal function in 
adolescents. The study included 36 subjects, including 23 hospitalized adolescent psychiatric 
patients (10 depressed e 13 non-depressed), of both sexes, belonging to the intervention group 
(15.8 ± 1.7 years). The control group consisted of 13 adolescents (16.9 ± 1.4 years) who 
underwent physical exercise for ten minutes on a stationary bike. Two samples of salivary 
cortisol were collected before the test, and four samples were taken after testing, at intervals 
of 20 minutes. In the intervention group, cortisol profiles were evaluated at two-hour intervals 
before and after administration of dexamethasone and hydrocortisone. There were no 
differences in basal cortisol levels between depressed and non-depressed groups. This study had 
important limitations. Among them, we can highlight that were compared two different types 
of cortisol response analysis (i.e., exercise in the control and suppression of dexamethasone and 
hydrocortisone in the experimental group). It was also not described the intensity that exercise 
was carried out on cycloergometer in the control group, either if these individuals had familiarity 
with the adopted ergometer and were physically active. It is known that trained and untrained 
individuals may have different magnitude of hormonal responses. It can also be noted that 
depression and dysthymia can cause different responses of HPA axis, and some individuals of 
the depressed group had dysthymia. Other relevant point is, the level of depression was not 
described, and a subjective classification of levels of depression was performed using a self-
report scale (SCL-90). In addition, the sample consisted of adolescents with enough variety of 
comorbidities and then, this study cannot be applicable to depressed adults. Kiive et al. [112] 
compared the responses of serum GH, prolactin and cortisol to cardiopulmonary 
cycloergometer test in depressed patients and healthy subjects. The study involved 46 adult 
males, including 24 depressed patients (43.5 ± 1.8 years) and 22 healthy volunteers (42.8 ± 3.0 
years). The control subjects and the depressed patients did not differ significantly in age, height, 
weight, or body mass index. The results showed an increase in cortisol secretion in response to 
acute exercise in both groups, but there was no significant difference in the concentration of 
this hormone between them. Therefore, the authors reported that the sample was small to 
allow a conclusive statistical analysis. Still, this experiment also led individuals to exhaustion, 
causing stress and expected elevation of cortisol. It would be interesting to apply an exercise 
protocol in lower intensities and chronic manner, so that possible differences could be found in 
the concentrations of this hormone between groups. Another possibility for failing to found any 
differences in cortisol responses between groups is that the patients used different drugs, where 
two outpatients did not report the use of antidepressant drugs, six patients were treated with 
tricyclic antidepressants (i.e., clomipramine, nortriptyline), eight patients with SSRI-s (i.e., 
fluoxetine, paroxetine, citalopram), three patients with mirtazapine and one patient with 
moclobemide. Four patients reported the use of antidepressants, but the type was not specified. 
Another limitation was no description of the level of depression, apart from the fact that 
patients were at different stages of treatment. Ida et al. [21] investigated the influence of an 
aerobic exercise session in cycloergometer for 15 minutes on salivary cortisol levels in depressed 
individuals. One month later, patients were invited to a control session where they sat quietly. 
If patient were using antidepressants before the entry, the dosage was fixed up to the end of 
the study. Salivary cortisol levels of each participant and the subjective scores of depressive 
symptoms were recorded before and after both sessions in order to examine the effect of 
exercise on depressive symptoms. One month after the exercise session, three participants drop 
out of control session. Both sessions had the same duration and were conducted in the same 
time of day. Seven patients were in clinical remission, ten had mild symptoms and one had 
moderate symptoms of depression. It is noteworthy that 17 out of 18 patients were physically 
active, but most (i.e., 12 patients) walking. Depressed patients who participated in the study 
were in remission or in mild depressive state. However, they did not have a good quality of life 
due to chronic depression. The level of salivary cortisol and depressive symptoms decreased 
significantly after the exercise session. In addition, changes in these variables were significantly 
positive. Furthermore, although subjective depressive symptoms had improved in the control 
session, the level of salivary cortisol did not change. However, this study had some limitations. 
First, the sample size was small and all patients were treated, and depressive symptoms varied 
among the study sample. Studies with patients free of antidepressants are necessary to avoid 
possible effects of medication on salivary cortisol concentrations. Another important factor is 
that patients were mostly in remission and had a mean of 61 months of disorder, and individuals 
treated with aerobic exercise at disease onset, suddenly, may have different responses from 
chronic individuals. Second, the scores of subjective depressive symptoms, assessing the change 
of subjective depressive symptoms, during the procedure were not sufficiently validated and 
should be confirmed in a future study with a larger sample size. In addition, it was not used any 
countered method to control the effects of order. Finally, perhaps the exercise protocol runtime 
has been insufficient to promote positive effects on cortisol changes (i.e., 15 min). Therefore, it 
is important the application of protocols to investigate the chronic effects of exercise on salivary 
cortisol concentration. As well as the perception of effort had been relatively low, perhaps 
activities performed in other intensities can promote distinct results. Perhaps because most 
studies have used a protocol of the incremental test [109-111], there were not found positive 
influences of exercise on cortisol. Nevertheless, studies that adopted the chronic form of 
exercise [32, 109] were different in the gender of the samples (male and female), in the age of 
the participants (adolescents and adults), in the levels of depression, and had a variety of 
instruments used to classify the disease and different exercise protocols. However, they applied 
the same intervention period (16 weeks). While Krogh et al. [109] found no influence of chronic 
aerobic exercise on the concentration of cortisol, Nabkasorn et al. [32] found a positive influence 
of chronic aerobic exercise on the concentration of this hormone. It is worth noting that the 
collection methods of cortisol were also different. While Krogh et al. [109] analyzed the plasma 
cortisol concentration, Nabkasorn et al. [32] analyzed the concentration of cortisol in urine. 
However, as mentioned above, the study by Nabkasorn was carried out on a nonclinical sample, 
i.e. without diagnosis of depression, while the ones by Garcia [110] Kiive [112] Krogh [109] and 
Wied [111] were carried out in clinical samples. Thus, further studies are needed so that the 
influence of aerobic exercise can be established in the concentration of cortisol in patients with 
depression. 
 
THE EFFECT OF AEROBIC EXERCISE ON THE PLASMA OR SERUM BDNF CONCENTRATIONS IN 
DEPRESSIVE PATIENTS 
There are few studies that analyzed the relationship between serum BDNF levels and aerobic 
exercise in patients with depression [113-117] (for review, see Tables 1 and 2). Gustafsson et al. 
[113] evaluated the response of plasma BDNF during incremental cycloergometer test. The 
study included 36 adult individuals of both genders, with 18 in the control group (34.5 years) 
and 18 belonging to the group with moderate depression (33.5 years). The depressed group did 
not use any type of antidepressant. The incremental test was performed with constant load 
period (six minutes) plus load increments every 30 seconds, until exhaustion. Serum BDNF levels 
were collected at the following times: pre-test; during the test, on the submaximal and maximal 
occasions; in the 30 and 60 minutes after completion. There was no difference in plasma 
concentration of BDNF in any of the moments between the two groups. However, it was 
observed an increase in BDNF concentration at 60 minutes after the end of the test, when 
compared to baseline, in depressed patients only. The same response did not occur in the 
control group. Thus, it appears that a single session of exercise cannot change the concentration 
of BDNF during acute exercise, exerting influence only 60 minutes after completion. 
Interestingly, BDNF levels at baseline did not differ between depressed patients and healthy 
controls, though other findings showed differences in plasma BDNF between depressed patients 
and healthy subjects [14, 118, 119]. Aiming to investigate the relationship between one exercise 
session and plasma levels of BDNF, Laske et al. [114] studied 55 adult women, 35 of which were 
depressed (61.1 ± 7.2 years) and 20 were healthy (58.9 ± 6.6 years). The exercise protocol chosen 
was the incremental treadmill test with an initial speed of 3km/h and load increments every 
three minutes. Blood samples were collected before the test, at the end of the test, and 30 
minutes after completion. There was a significant increase in plasma BDNF right after finishing 
the test in depressed patients compared to pre-test and 30 minutes after completion. This 
decrease in plasma levels of BDNF at 30 minutes after the test showed that an exercise session 
seems to be able to promote a chronic expected increase in concentration of this biomarker. 
However, these patients were women with moderate to severe depression in clinical remission. 
Thus, it is necessary to investigate whether patients with different degrees of depression, of 
both gender and other age range would respond the same way to this intervention. 
Nevertheless, depressed patients who participated in this study used antidepressants, which 
could be a bias with respect to the role of exercise on the BDNF concentration. Zoladz et al. [120] 
showed that after five weeks of aerobic exercise performed on a bicycle, and not just an 
incremental session, there was an increase in basal levels of BDNF in young healthy men and 
women. Thus, it appears that regular exercise plays an important role in plasma BDNF; however, 
the acute exercise does not influence significantly the levels of this biomarker. Toups et al. [115] 
compared the plasma concentrations of BDNF in two groups of subjects with moderate 
depression, divided into high-caloric expenditure exercise and low calorie expenditure exercise. 
The study was conducted for 12 weeks, and included 95 subjects aged 18 to 70, 46 belonging to 
the group of low caloric expenditure (46.1 years) and 49 to the group of high caloric expenditure 
(49.2 ± 9.1 years). After intervention, no difference was detected in serum BDNF levels in 
relation to pre-test, where the concentration remained stable. Also, there was no difference 
between the two groups in plasma BDNF. These findings do not corroborate those of Zolads et 
al. [120], showing that even the long-term study was not able to promote positive changes in 
plasma concentration of BDNF. Something that should be highlighted is that the authors did not 
describe the adopted protocol of exercises (i.e., mode, intensity and duration), only mentioning 
it was high versus low calorie expenditure. Importantly, the sample was composed mostly of 
obese women. Thus, the results cannot be generalized to depressed thin male patients, for 
example. In addition, pre-treatment  
 
 
 with SSRI (selective serotonin reuptake inhibitors) may have masked the effect of exercise on 
BDNF. It is also noteworthy that the study lacked a control group. The practice of different 
protocols (i.e., different duration and intensities) is needed to clarify this issue. Salehi et al. [116] 
carried out a randomized study and showed that 4 weeks of electroconvulsive therapy, aerobic 
exercise and both were able to increase serum BDNF levels and reduce depressive symptoms in 
60 depressed patients. However, patients were treated with a SSRI antidepressant (i.e., 
citalopram). Therefore, one cannot determine whether the individuals had improvements in 
depressive symptoms and an increase in the plasma levels of BDNF due to electroconvulsive 
therapy and aerobic exercise. It is also noteworthy that this study lacked a control group too, 
and then it would be interesting to carry out a controlled study, with use of citalopram and 
without exercise practice. Moreover, the sample was mostly constituted by young males 
individuals (n = 41) with severe depression, and thus, these results cannot be extrapolated for 
an elderly population of depressed women, for example. Furthermore, the time interval 
between pre- and post-assessment has been established in four weeks, and there was no further 
evaluation or follow-up, which would have been enlightening to observe long-term changes in 
plasmatic BDNF and psychopathology. It is still unclear to what extent the peripheral BDNF 
effectively reflects BDNF availability in the CNS. Also, due to the importance of the HPA axis in 
depression, studies are needed to examine the activity of the HPA axis and its interaction with 
plasmatic BDNF. Schuch et al. [117] showed no difference in plasma BDNF levels after treatment 
associated with aerobic exercise of moderate to vigorous intensity. All patients (15 exercise and 
11 control) received concurrently other therapies such as pharmacotherapy and 
electroconvulsive therapy (ECT). As shown in the study of Salehi et al. [116], ECT alone is already 
able to increase levels of BDNF in depressed patients. Mata et al. [36] have shown that some 
genotypes can moderate BDNF responses to exercise. Furthermore, the study lasted only three 
weeks, which cannot lead to significant changes in the levels of BDNF. Thus, further studies with 
large sample, long-term duration and no drugs are necessary. It would also be interesting to 
compare different aerobic exercise intensities, so that there is a consensus on the true role of 
this type of exercise on BDNF levels of depressed individuals. This discrepancy may be due to 
the use of different samples and different exercise protocols. Toups et al. [115] performed a 
study on a chronic basis. Gustafsson et al. [113] and Laske et al. [114] applied the incremental 
test. Even so, the ergometers used were different. Gustafsson et al. [113] used the 
cycloergometer and Laske et al. [114] used the treadmill. The fact that there are few studies, 
and these few have used different exercise protocols and heterogeneous samples, does not 
allow us to draw a relationship between aerobic exercise and BDNF. Therefore, it becomes 
necessary to perform more studies with other groups of depressed patients, so it can be clarified 
the relationship between BDNF and aerobic exercise (for review, see Tables 1 and 2). 
 
NEUROBIOLOGICAL MECHANISMS 
The neurobiological effects of exercise acting as an agent that can modulate mood appears to 
influence several neural mechanisms that are related to depression [16, 121]. There is evidence 
that the practice of exercise causes physiological changes in monoamine levels in rats [122], as 
well as in healthy men and women [123], alters the levels of cortisol in rats and healthy 
individuals [123-126] and leads to adaptations in limbic structures that have been implicated in 
depression, in addition to increased expression of neurotrophic factors in hippocampus of rats 
and healthy subjects [121, 125-131]. However, no evidence was obtained in depressed patients. 
A dysfunction in the serotonin (5-Hydroxytryptamin; 5HT) has been identified as the immediate 
cause of depression [132, 133]. A decrease in the levels of 5- hydroxyindoleacetic (5HIAA), the 
major metabolite of 5-HT on the human body, a decrease in plasma tryptophan acid, as well as 
low proportion of amino acid tryptophan and 5HT function abnormalities are commonly 
reported in studies of depression [134, 135]. It is noteworthy that the increase in monoamine 
levels can be achieved by the practice of chronic exercise. For example, significant levels of 
noradrenaline and 5HT and 5HIAA and the expression of 5-HT2C receptors in the limbic system 
have been reported in experimental animals following chronic exercise treadmill [122, 125, 136, 
137]. While the activation of the HPA axis can be considered an adaptive mechanism based on 
the response to change, a high, prolonged activation of this system represents a health risk. 
Chronic stress is linked to hyperactivity of the HPA axis and elevated levels of glucocorticoids 
[138, 139]. Most groups of depressive patients display alterations in the HPA system, resulting 
in altered regulation of ACTH and secretory activity of cortisol [19, 140]. Rubin et al. [141] 
observed high levels of ACTH and cortisol secretion in depressed patients. Exercise, like other 
stressors, activates the sympathetic nervous system, resulting in the secretion of glucocorticoids 
[142, 143]. However, physically active people show different cortisol responses to acute exercise 
compared to less active individuals. Cortisol levels in physically active individuals is attenuated 
and dissipates more rapidly than in less active individuals [123, 124, 144]. Therefore, exercise 
can reduce symptoms of depression by its influence on the HPA system, attenuating the 
glucocorticoid response to stressful stimuli. Depression can lead to neuronal cell loss and 
atrophy in limbic regions of the brain, including the amygdala, and prefrontal cortex and 
hippocampus [11]. Depression is related to a decline in cognitive function in which the 
hippocampus plays a crucial role. Hippocampal neurogenesis has been associated with 
improvements in learning and memory function [145, 146]. The hippocampus is also involved in 
regulation of the HPA axis in response to stress the system. Damage or atrophy of the 
hippocampus impairs this system, leading to a prolonged activation of the HPA axis in response 
to psychological stressors [147, 148]. High levels of glucocorticoid induce atrophic changes in 
sub-regions of the hippocampus [147], which is consistent with the reduction in volume of the 
hippocampus seen during depression. Patients with depression have shown smaller 
hippocampal volume than non-depressed controls [149]. The left hemisphere showed a 
significant reduction in the volume of the hippocampus in 19% of depressed patients compared 
with healthy controls. These results suggest that depression causes a loss of brain volume 
observed in the hippocampus, especially in the left hemisphere. As mentioned earlier [142, 143], 
the exercise, as well as other stressors, activates the sympathetic nervous system, resulting in 
the secretion of glucocorticoids. It has been shown that stress can reduce the expression of 
several neurotrophic growth factors in the hippocampus, while chronic antidepressant 
treatment acts on the opposite way [5]. Among the protective effects of exercise stress, we can 
highlight neurogenesis [129, 150] and the expression of the growth factor in the hippocampus 
[13]. Different stressful stimuli, such as acute immobilization stress [151] or administration of 
corticosterone [152], reduce the expression of neurotrophic factors in the hippocampus. Human 
studies have shown that the availability of BDNF deficiency is associated with vulnerability to 
depression [153]. Exercise training therefore compensates the atrophic changes of the 
hippocampus for its impact on the expression of neurotrophic growth factors, which have an 
antidepressant action similar to that hypothesized for the treatment of antidepressant drugs 
[127, 130, 154-157]. Thus, there is support for the neurotrophic hypothesis of depression as an 
alternative to any other hypothesis. In summary, these neurobiological results tend towards that 
the health of the brain depends from exercise, and that the regular practice should be promoted 
as prevention and rehabilitation strategy to prevent or treat brain related diseases. 
 
CONCLUSION 
In this review on the effect of aerobic exercise on serum BDNF and cortisol in patients with 
depression, 11 studies were incorporated, aggregating a total of 508 individuals with MD, and 
137 healthy controls. Of these eleven studies, six evaluated the relationship between exercise 
and cortisol, and five examined the relationship between exercise and BDNF. In general, no 
relationship was established on the impact that exercise has on the concentration of these two 
biomarkers. This may be explained by the difference across variables such as: type of exercise 
adopted; duration of the session; prescribed intensity and frequency of weekly sessions. It 
seems that just an exercise session is not able to influence in positive adaptations in cortisol 
levels and BDNF. Mistakenly, most of the papers, a total of five, adopted the cardiopulmonary 
effort test as aerobic exercise. However, it is noteworthy that the cardiopulmonary exercise test 
is, in most cases, an anaerobic activity, due to its intensity, which is submaximal or maximal, 
thus exceeding the anaerobic threshold of these individuals. Furthermore, only two studies have 
examined the chronic effects of physical exercise in concentration of cortisol, and one study 
adopted chronic exercise to investigate its role on plasma concentrations of BDNF. Thus, it would 
be interesting to conduct further studies on aerobic exercises in a chronic way, to establish a 
genuine cause and effect relationship between regular exercise and the investigated 
biomarkers. 
 
LIST OF ABBREVIATIONS  
5-HT2C = 5-Hydroxytryptamin (Serotonin) Receptor 2C  
5HIAA = Hydroxyindoleacetic Acid  
5HT = 5-Hydroxytryptamin  
ACSM = American College of Sports Medicine  
ACTH = Adrenocorticotropin  
BDNF = Brain Derived Neurotrophic Factor  
CNS = Central Nervous System HPA = Hypothalamic-Pituitary-Adrenal Axis MD = Major 
Depression SSRI = Selective Serotonin Reuptake Inhibitor 
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